Dysostosis Multiplex
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) (NCT02298647) | CENTOGENE GmbH Rostock | 2018-08-20 |
Track Dysostosis Multiplex automatically
Every clearance here is in the API, with alerts when new ones post.